Liven Pharma Limited reported a revenue of Rs 29.25 million for the quarter ended March 31, 2026
Filed as: Financial Results for the 3rd Quarter Ended 31st March 2026
Summary
Liven Pharma Limited reported a revenue of Rs 29.25 million for the quarter ended March 31, 2026, showing a significant increase from the previous year. Despite an operating loss, the company reduced its net loss to Rs 3.96 million.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 29.25 M | PKR 14.75 M | +98.3% |
| Gross Profit | PKR 8.42 M | PKR 3.74 M | +125.2% |
| Operating Loss | PKR -5.53 M | PKR -7.31 M | +24.3% |
| Net Loss After Tax | PKR -3.96 M | PKR -9.62 M | +58.9% |
| Earnings Per Share (EPS) | PKR -0.03 | PKR -0.10 | +70.0% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased to Rs 29.25 million from Rs 14.75 million, a growth of 98.27% compared to the prior period.
- Gross profit rose to Rs 8.42 million from Rs 3.74 million, reflecting a strong improvement in profitability.
- The net loss after tax was reduced to Rs 3.96 million from Rs 9.62 million, indicating better cost management and operational efficiency.
Liven Pharma Limited (LIVEN) on Nafa
Last price Rs 39.19 · Pharmaceuticals · You can own LIVEN shares from your phone.
More LIVEN announcements
- NoticeGeneral Meetings / Briefing Sessions
- NoticeNotice of Corporate Briefing Session
- Financial resultLiven Pharma Limited reported a significant loss of Rs 7.37 million for the period ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30-2026
- NoticeBOARD MEETING FOR 1st Quarter Financials 2027
- NoticeCertified True Copy of Resolution Passed in Annual General Meeting Held 26th October 2026
- NoticeCorrection Clarification Regarding Annual Report 2026
Source: Liven Pharma Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.